Business Context and Reporting Period
Company: Bioaffinity Technologies, Inc. (BIAF)
Filing Type: Form 8-K (Current Report)
Date of Report: September 17, 2026
Reporting Period: Single event date (September 17, 2026)
Business Context: The Company is a Delaware corporation focused on proprietary technology for predicting the likelihood of lung cancer using flow cytometry and fluorescent markers to characterize cell populations in sputum.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a Current Report on Form 8-K regarding a specific corporate event and does not contain financial statements or performance metrics.
Material Changes
Intellectual Property Grant: On September 17, 2026, the Hong Kong Intellectual Property Department granted a patent for the Company's proprietary lung cancer prediction technology. This represents a material development in the Company's intellectual property portfolio.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release (Exhibit 99.1) announcing the patent grant. No specific financial guidance, future outlook, or risk factors were detailed within the text of this 8-K filing.
Unusual Items: None reported beyond the standard patent grant announcement.
Investor Verification Checklist
- Verify the scope and enforceability of the patent granted by the Hong Kong Intellectual Property Department.
- Review the attached press release (Exhibit 99.1) for details on the commercial application of the patented technology.
- Confirm the Company's status as an emerging growth company and its implications for future reporting.
- Check subsequent filings for any financial impact or revenue recognition related to this intellectual property.